| Status: Recommended | ||
Sofosbuvir/velpatasvir (Epclusa®) is recommended as an option for use within NHS Wales for the treatment of chronic hepatitis C virus (HCV) infection in patients from 3 years of age to < 18 years of age, in line with the National Institute of Health and Care Excellence recommendation for the use of sofosbuvir/velpatasvir for treating chronic HCV infection in adults (TA430). |
||
|
||
Medicine details |
||
| Medicine name | sofosbuvir/velpatasvir (Epclusa®) | |
| Formulation | 150 mg/37.5 mg coated granules, 200 mg/50 mg coated granules | |
| Reference number | 4573 | |
| Indication | Treatment of chronic hepatitis C virus (HCV) infection in patients from 3 years of age to less than 18 years of age |
|
| Company | Gilead Sciences Ltd | |
| BNF chapter | Infections | |
| Assessment type | Licence extension for paediatric use | |
| Status | Recommended | |
| Advice number | 0123 | |
| AWMSG meeting date | 08/02/2023 | |
| Date of issue | 15/02/2023 | |